revascularization and cerebral vascular accidents) 1 year after DES implantation in the Pio-treated group was significantly decreased (6.6%) compared with that with other therapies in the group without Pio (12.0%, P< 0.01). The rate of CV events 3 years after DES implantation in the Pio-treated group was significantly decreased (10.6%) compared with that with other therapies in the group without Pio (19.1%, P< 0.01). Conclusions: Pioglitazone significantly decreases CV events of Japanese patients with DM after DES implantation according to 1-year and 3-year follow-up results.
Background: Diabetes mellitus is a risk factor for poor outcomes after PCI. The newer-generation metallic drug-eluting stents (DES) have improved outcomes in nondiabetics, but outcomes remain poor in diabetics. Bioresorbable scaffolds are novel devices for coronary revascularization; however, long-term clinical outcomes of these devices in diabetics have not been reported. Aim of this study was to evaluate 2-year clinical outcomes in diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds (BVS). Methods: We compared outcomes in 142 diabetics and 434 non-diabetics treated with BVS from Absorb Cohort B and Absorb EXTEND. Furthermore, BVS treated diabetics (n¼103) were compared with propensity matched diabetics (n¼175) treated with metallic XIENCE everolimus-eluting stents (EES) from SPIRIT First, II, III and IV studies. Patient-oriented composite endpoint (PoCE, including all death, all MI, and all revascularizations), device-oriented composite endpoint (DoCE, including cardiac death, target vessel MI, or target lesion revascularization) and scaffold/ stent thrombosis (definite and probable according to ARC) were assessed at 2-year follow-up.
Results: BVS treated diabetics had similar baseline characteristics as BVS treated non-diabetics except for the presence of diabetes and hypertension. At 2-year followup, there were no significant differences in PoCE (diabetics 10.6% vs non-diabetics 12.9%, p¼0.46), DoCE (diabetics 4.2% vs non-diabetics 7.6%, p¼0.16) and scaffold thrombosis (diabetics 0.7% vs non-diabetics 0.9%, p¼1.0) between the two groups. BVS and EES treated diabetics were well-matched for demographic, clinical and procedural characteristics, except for longer duration of DAPT in the BVS group. PoCE (BVS 12.6% vs EES 10.9%, p¼0.66), DoCE (BVS 5.8% vs EES 5.7%, p¼0.97) and scaffold/stent thrombosis (BVS 1.0% vs EES 0.6%, p¼1.0) were similar in the diabetics treated with BVS or EES at 2-year follow-up. Conclusions: Patient-and device-oriented outcomes in BVS treated patients were independent of diabetic status, and were comparable to the outcomes observed with EES. A prospective randomized clinical trial is warranted to determine the optimal device for diabetic patients.
TCT-246
Feasibility and mid-term outcome of everolimus-eluting bioresorbable vascular scaffolds in diabetics Justus-Liebig University of Giessen, Giessen, Germany Background: Diabetes is associated with diffuse coronary artery disease and worse clinical outcome after stenting with metallic stents. Everolimus-eluting bioresorbable vascular scaffolds (BVS, Abbott Vascular, Santa Clara, California, USA) represent a new approach. This study aimed to evaluate feasibility and mid-term clinical outcome after implantation of BVS in diabetics. Methods: All patients with diabetes who had been treated with BVS in the vicinity of our all-comers registry were included, irrespective of their clinical presentation. Target parameters were target vessel failure (TVF), major adverse cardiac events (MACE) including target lesion revascularization (TLR), cardiac death, myocardial infarction and emergency coronary bypass graft surgery. Follow-up was performed by telephone call and/ or office visit. Results: A total of 100 patients were included, of whom 15 % had a STEMI, 20 % a NSTEMI, 13 % presented instable angina and 52 % stable angina. Median age was 67 (60-73) years, 29 % were female, 97 % suffered from hypertension. Of all patients, 36 % patients have an insulin-dependent diabetes, all other patients were treated with oral antidiabetics or dietary. Median procedure time was 56.5 min (41 -70), mean contrast volume was 178.3 mL (AE 92.3). A total of 105 bioresorbable vascular scaffolds were implanted with a mean number of 1.4 AE 0.8 per patient. There was no implantation possible in two cases. Median follow-up duration was 175 (59 -316) days. Three scaffold thromboses occurred, of which two were most probably due to discontinuation of dual antiplatelet therapy. One in-scaffold restenosis was noted. In summary the total rates of TVF, TLR and MACE were 5.1, 4.1 and 8.0 %, respectively. Conclusions: Since the experience with bioresorbable vascular scaffolds in specific subsets is limited, this study confirms safety of bioresorbable vascular scaffold implantation in diabetics. Furthermore our results demonstrate satisfying mid-term clinical outcome. DAPT seems to be extraordinary crucial to prevent scaffold thrombosis. Nevertheless, long-term data is required for final evaluation. Background: Percutaneous coronary intervention (PCI) of small vessels has been associated with high risk of recurrent events, especially in patients with diabetes mellitus (DM). Methods: We examined outcomes of patients with small reference diameter ( 2.5 mm) vessels who underwent PCI using ResoluteTM zotarolimus-eluting stent (R-ZES) in the pooled RESOLUTE program stratified by diabetic status. Target Lesion Failure (TLF) was composite of death from cardiac causes, target vessel myocardial infarction (TV-MI), and target lesion revascularization (TLR). The incidence of clinical events was calculated using the Kaplan Meier method. Results: Among 2721 patients with at least one small vessel lesion treated with R-ZES, 233 patients had insulin dependent DM (IDDM), 724 patients had non-insulin dependent diabetes mellitus (non-IDDM), and 1764 patients did not have diabetes (no-DM). There were significant differences in baseline characteristics, in particular greater complexity with IDDM patients. At 3-years, TLR was similar in non-DM and NIDDM, and was significantly lower than in IDDM patients (Figure) . Similarly, TLF (9.7% vs. 11.1% vs. 21.8%, p< 0.001), CD/TV-MI (5.6% vs. 7.4% vs 11.8%, p¼0.002), and ARC Definite/Probable ST (0.9% vs. 1.1% vs. 1.3%, p¼0.81), were lower among non-DM and NIDDM patients. Conclusions: Among patients undergoing PCI with small vessels in the pooled RESOLUTE program, NIDDM and non-DM patients had similar 3-year outcomes, which was lower than with IDDM. These outcomes demonstrate the long-term safety and effectiveness of R-ZES in complex NIDDM and non-DM patients. Submitted on behalf of the RESOLUTE Global Clinical Program Background: There is currently no data to evaluate the differences of drug-eluting stents on the angiographic outcomes of diabetes mellitus (DM) patients. To evaluate the effects of different drug-eluting stents on the outcomes of DM patients, we investigated serial angiographic outcomes after drug-eluting stent placement. Methods: From 2002 to 2012, 10983 consecutive de-novo coronary lesions were treated using drug-eluting stents (biolimus-eluting stent (BES); n¼1367, everolimuseluting stent (EES); n¼2983, paclitaxel-eluting stent (PES); n¼1215, sirolimuseluting stent (SES); n¼5418). 41% were DM and 10% were insulin-treated patients. Angiographic follow-up was routinely performed 8 months after a successful procedure (follow-up rate was 82%). Angiographic outcomes were compared among patients with the implanted stent types. Results: The binary restenosis rates were 6.6% in non-DM patients, 11.0% in noninsulin-requiring DM patients, and 14.0% in insulin-treated DM patients. The SES, PES and BES groups had higher restenosis rates in non-insulin-requiring DM patients compared with non-DM patients (SES; 6.1% vs. 10.4%, p< 0.001, PES; 12.0% vs. 21.7%, p< 0.001, BES 5.9% vs. 9.1%, p¼0.04). Binary restenosis in the EES group were similar between non-DM patients and non-insulin-requiring DM patients (5.5% vs. 5.6%, p¼0.92). A multivariable analysis showed that DM was an independent predictor of recurrent restenosis in implantation of SES (odds ratio [OR] Background: To evaluate whether the impact on clinical outcomes of newer vs. first generation drug-eluting stents (DES) is influenced by diabetes mellitus (DM). Methods: We pooled patient-level data of 10,448 women undergoing PCI with DES from 26 randomized trials. Baseline characteristics and long-term clinical outcomes were stratified according to baseline DM status and DES type (new vs. first generation). Associations between stent type and outcomes were examined within each stratum using Cox regression with trial entered as a random effect. The primary endpoint was the composite of all-cause death and myocardial infarction (MI). Secondary endpoints were target-lesion revascularization (TLR) and definite or probable stent thrombosis (ST). Results: DM was present in 3,294 (31.5%) of women treated with DES. In women without DM, use of new generation compared with first generation DES was associated with reduced risks of death or MI (7.6% vs. 10.2%; adjHR 0.69, 95%CI, 95%CI 0.55-0.88), ST (0.8% vs. 1.7%; adjHR 0.32, 95%CI 0.17-0.62) and TLR (5.3% vs.
6.9%; adjHR 0.74, 95%CI 0.56-0.99). No major differences were observed between new and first generation DES for death or MI (12.8% vs. 12.4%; adjHR 0.90, 95%CI, 95%CI 0.69-1.19), ST (2.0% vs. 3.1%; adjHR 0.84, 95%CI 0.47-1.49) and TLR (8.7% vs. 9.5%; adjHR 1.14, 95%CI 0.82-1.59) among women with DM ( Figure) . Interaction testing was significant for the outcome of def/prob ST (p¼0.04 .001) were significantly higher in the ZES group, whereas implantation of smaller vessel stents ( 2.5mm) was statistically higher in the EES group (27.6% vs. 37.8%, p¼0.015). At the follow-up period of 720 days, there was no significant difference in MACE between ZES and EES (22.8% vs. 18.1%, HR¼1.11, 95%CI: 0.67-1.85). Similarly no significant differences were observed in the composite endpoint of death or MI (9.1% vs. 10.3%, HR¼1.14, 95%CI: 0.54-2.40) or TLR (12.4% vs. 6.9%, HR¼1.53, 95%CI; 0.81-2.89). Conclusions: The present study showed that no significant differences in each outcomes (MACE, all-cause mortality/MI, TLR) were observed in diabetic patients treated with new-generation cobalt-chromium ZES and EES. Even though, our study cohort constituted of more complex lesions and patient characteristics, our findings resemble the ones reported in previous randomized control studies in the general population.
Lipid Disorders and Management
Washington Convention Center, Lower Level, Hall A Saturday, September 13, 2014, 5:00 PM-7:00 PM Background: Reducing the expression of endothelial cell adhesion molecules (ECAMs) is conducive to the decrease of inflammation-induced vascular complications. In this study, we observed Pitavastatin on the expression of vascular cell adhesion molecule-1 (VCAM-1) and its influence on VCAM-1's target gene miR-126 in cultured human umbilical vein endothelial cells (HUVEC) activated by tumor ncrosis factor-a (TNF-a). The purpose of this study is to explore the mechanism of pitavastatin in prevention and treatment of atherosclerosis (AS). Methods: HUVEC were cultured in M1640 supplemented with 10% bovine calf serum and passages 2 to 5 were used in experiments. The cells were randomly divided into three
